During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated ...

In an interview with Targeted OncologyTM, Dong Chen, MD, PhD, hematopathologist and vice chair of practice in pathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in ...

Advanced molecular targeted imaging: These studies, with promising results reported for DICER, aim to visualize residual disease with greater sensitivity. Radiomics imaging: This emerging field ...

THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

Branding in the health care industry should prioritize communicating empathy and care through every touchpoint.

Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.

Panelists discuss how the choice between hydroxyurea (HU) and interferon (IFN) for cytoreductive therapy in polycythemia vera ...

Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.

Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.